THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX
Delisted
THRX was delisted on the 13th of February, 2024.
69 hedge funds and large institutions have $374M invested in Theseus Pharmaceuticals, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
69
Holders Change
-3
Holders Change %
-4.17%
% of All Funds
1.09%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
10
Increased
27
Reduced
13
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$13.1M |
| 2 |
BlackRock
New York
|
+$4.2M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.15M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$1.62M |
Top Sellers
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$16.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.87M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.63M |
| 4 |
Walleye Capital
New York
|
-$1.59M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.28M |
